Orchard Therapeutics (Nasdaq: ORTX) reported progress in its gene therapy programs for neurometabolic disorders, with key updates on Libmeldy (OTL-200) for MLD and OTL-203 for MPS-I. The company submitted responses to EMA regarding Libmeldy's marketing application and received FDA designations for OTL-203. Financially, Orchard reported Q2 2020 R&D expenses of $31.6 million, down from $40.5 million in Q2 2019. The net loss for the quarter was $47.5 million, slightly improved from $50.5 million year-over-year. With $228.7 million in cash, the company expects to fund operations into 2022.
Orchard Therapeutics (Nasdaq: ORTX) has received orphan drug and rare pediatric disease designations from the FDA for its gene therapy OTL-203, aimed at treating mucopolysaccharidosis type I (MPS-I). This recognition highlights the urgent need for therapeutic options for MPS-I patients. The designations afford benefits such as tax credits for clinical testing and market exclusivity. Early trial data indicates successful hematologic engraftment in eight patients. Full results and a registrational study are expected to be announced in 2021.
Orchard Therapeutics (Nasdaq: ORTX) has entered into two royalty-bearing license agreements with GlaxoSmithKline for their lentiviral stable cell line technology, enhancing its hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia. This technology promises efficient viral vector production, reducing costs and production time, potentially providing a competitive advantage. Orchard plans to submit biologics license applications for OTL-103 in 2021, though the licensing terms won't materially impact its financial position or cash needs.
Orchard Therapeutics (Nasdaq: ORTX) announced positive interim results from its ongoing clinical trial for OTL-203, an ex vivo gene therapy for mucopolysaccharidosis type I (MPS-I). All eight patients treated achieved hematologic engraftment within 45 days, marking a primary outcome measure. Significant improvements were observed in motor skills and cognitive functions in the first two patients, with continued normal growth. The company anticipates initiating a registrational trial in 2021 and plans to report more interim results later in 2020.
Summary not available.
Summary not available.
Summary not available.